Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06126393
Other study ID # CHENJIAN1
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 1, 2024
Est. completion date June 30, 2027

Study information

Verified date November 2023
Source Fujian Cancer Hospital
Contact Jian Chen, Master
Phone 15806030009
Email marsz3@126.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Molecular typing provides accurate information for the diagnosis, treatment and prognosis prediction of endometrial cancer, which has important clinical significance. However, due to its high cost and complicated process, it is difficult to be widely used in clinical practice. Based on the artificial intelligence method, this study fused the characteristics of MRI radiomics and pathomics, combined with the clinical pathological information, built a model to predict the molecular typing and prognosis, analyzed the biological characteristics of endometrial cancer from the multi-scale level, guided the personalized and precise diagnosis and treatment, in order to improve the prognosis of patients.


Description:

In this project, 150 cases of endometrial cancer were retrospectively collected, and 200 cases of endometrial cancer will be prospectively collected. All patients were pathologically confirmed and underwent Promise molecular typing. Before treatment, all patients completed abdominal MRI. Based on artificial intelligence technology, image features were extracted from magnetic resonance imaging, pathological features were extracted from pathological data, and clinical pathological data were collected at the same time. The treatment effect, recurrence and metastasis of patients were followed up, and the five-year survival rate and five-year progression free survival rate were calculated. It is proposed to focus on the following research: 1. Construction of molecular typing and prognosis prediction model of endometrial cancer based on magnetic resonance imaging Radiomics 2. Construction of molecular typing and prognosis prediction model of endometrial cancer based on pathomics. 3. Construction of a prediction model for molecular typing of endometrial cancer by integrating pathomics and radiomics.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 350
Est. completion date June 30, 2027
Est. primary completion date March 31, 2027
Accepts healthy volunteers
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - •Pathologically confirmed as endometrial malignant tumor with complete pathological H&E stained sections; - Age = 18 years and = 80 years; - No other malignant cancers was found; - The complete immunohistochemical and second-generation sequencing results can be used for the molecular typing of ProMisE; - Magnetic resonance examination was performed within 2 weeks before treatment, and there was at least one measurable lesion according to RECIST 1.1 Criteria. Exclusion Criteria: - • The image quality is poor or the tumor is too small due to serious graphic artifact and degeneration, and the ROI cannot be accurately delineated; - Patients who received any antitumor therapy before surgery; - Diagnostic endometrial biopsy before MRI

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
next generation sequencing AND Immunohistochemical examination
First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.

Locations

Country Name City State
China Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou Fujian

Sponsors (4)

Lead Sponsor Collaborator
Fujian Cancer Hospital First Affiliated Hospital of Fujian Medical University, Fujian Provincial Hospital, Gutian Hospital

Country where clinical trial is conducted

China, 

References & Publications (6)

Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022 Apr 9;399(10333):1412-1428. doi: 10.1016/S0140-6736(22)00323-3. — View Citation

Hou L, Zhou W, Ren J, Du X, Xin L, Zhao X, Cui Y, Zhang R. Radiomics Analysis of Multiparametric MRI for the Preoperative Prediction of Lymph Node Metastasis in Cervical Cancer. Front Oncol. 2020 Aug 20;10:1393. doi: 10.3389/fonc.2020.01393. eCollection 2 — View Citation

Jamieson A, McAlpine JN. Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice. J Natl Compr Canc Netw. 2023 Feb;21(2):210-216. doi: 10.6004/jnccn.2022.7096. — View Citation

Lefebvre TL, Ueno Y, Dohan A, Chatterjee A, Vallieres M, Winter-Reinhold E, Saif S, Levesque IR, Zeng XZ, Forghani R, Seuntjens J, Soyer P, Savadjiev P, Reinhold C. Development and Validation of Multiparametric MRI-based Radiomics Models for Preoperative — View Citation

Song XL, Luo HJ, Ren JL, Yin P, Liu Y, Niu J, Hong N. Multisequence magnetic resonance imaging-based radiomics models for the prediction of microsatellite instability in endometrial cancer. Radiol Med. 2023 Feb;128(2):242-251. doi: 10.1007/s11547-023-0159 — View Citation

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015 Jul 14;113(2):299- — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Application of pathomics to construct a model for predicting the molecular classification and prognosis of endometrial cancer The pathomics features of endometrial cancer patients were extracted by artificial intelligence method. Combined with clinicopathological risk factors and survival time, an imaging nomogram was constructed by lasso regression method to predict the molecular classification and prognosis of endometrial cancer. ROC curve was used to evaluate the test efficiency of the model. 2026-12-21
Primary Application of magnetic resonance imaging radiomics and pathomics to construct a model for predicting the molecular classification and prognosis of endometrial cancer The imaging and pathological features of endometrial cancer patients were extracted by artificial intelligence method. Combined with clinicopathological risk factors and survival time, an imaging nomogram was constructed by lasso regression method to predict the molecular classification and prognosis of endometrial cancer. ROC curve was used to evaluate the test efficiency of the model. 2026-12-21
Secondary Application of magnetic resonance imaging radiomics to construct a model for predicting the molecular classification and prognosis of endometrial cancer The imaging features of endometrial cancer patients were extracted by artificial intelligence method. Combined with clinicopathological risk factors and survival time, an imaging nomogram was constructed by lasso regression method to predict the molecular classification and prognosis of endometrial cancer. ROC curve was used to evaluate the test efficiency of the model. 2026-12-21
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06409039 - POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation
Completed NCT02865889 - Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications N/A
Completed NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) Phase 1/Phase 2
Active, not recruiting NCT05682950 - Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer Phase 2
Not yet recruiting NCT05974995 - Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer N/A
Recruiting NCT03291106 - Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer
Recruiting NCT03291275 - Survival Outcomes of Uterine Malignancies in Chinese Population N/A
Completed NCT00341458 - Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics
Terminated NCT05067972 - A Study of PF-07260437 in Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05795244 - Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) Phase 2
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Active, not recruiting NCT04865289 - Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study Phase 3
Completed NCT03270995 - Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study N/A
Terminated NCT01969396 - Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology N/A
Completed NCT01460979 - Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma Phase 2
Active, not recruiting NCT05869123 - Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer Phase 1/Phase 2
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Active, not recruiting NCT05588076 - Endometrial Lesions Predictions